Autoimmune drugmaker Immunovant's Q2 net loss misses estimates

Reuters11-10
Autoimmune drugmaker Immunovant's <a href="https://laohu8.com/S/QTWO">Q2</a> net loss misses estimates

Overview

  • Immunovant Q2 net loss misses analyst expectations

  • Company advances IMVT-1402 trials across multiple indications, contributing to increased R&D expenses

  • Immunovant maintains strong cash position, supporting trials through GD readout in 2027

Outlook

  • Company plans to report IMVT-1402 trial results in 2026 and 2027

  • Current cash supports operations through GD readout in 2027

Result Drivers

  • INCREASED R&D EXPENSES - Higher R&D expenses due to clinical trials of IMVT-1402, including contract manufacturing costs and personnel-related expenses

  • Research and development (R&D) expenses were $114.2 million for the three months ended September 30, 2025, compared to $97.3 million for the three months ended September 30, 2024

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Net Income

Miss

-$126.50 mln

-$123.42 mln (12 Analysts)

Q2 Basic EPS

-$0.73

Q2 Operating Expenses

$131.76 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Immunovant Inc is $44.00, about 46.9% above its November 7 closing price of $23.35

Press Release: ID:nGNX4rSpJy

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment